Novartis Prostate Cancer Drug Trial Meets Primary Endpoint
05 Dezembro 2022 - 3:57AM
Dow Jones News
By Cecilia Butini
Novartis AG said Monday that a trial to evaluate prostate-cancer
drug Pluvicto met its primary endpoint in patients with a specific
type of metastatic cancer.
The Swiss drug company said the primary endpoint was to improve
progression-free survival, or the time in which patients can live
without the disease advancing.
The data will be submitted for regulatory approval next year to
the U.S. Food and Drug Administration , Novartis said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
December 05, 2022 01:42 ET (06:42 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
